Antibody Drug Conjugate Market
完整報告名稱與涵蓋範圍
Antibody Drug Conjugate Market Size, Share & Trends Analysis Report, By Payload Type (Auristatins, Topoisomerase I Inhibitor Payloads, Maytansinoids, Calicheamicins), By Linker Type (Cleavable Linkers, Non Cleavable Linkers), By Indication (Breast Cancer, Urothelial Cancer, Lymphomas, Lung Cancer), By Region, and Segment Forecasts, 2026-2035
報告摘要
Antibody drug conjugates couple a tumor-targeting monoclonal antibody to a cytotoxic payload through an engineered linker, concentrating chemotherapy inside antigen-expressing cells while sparing healthy tissue. The market covered here includes approved conjugates across hematology and solid tumors, together with the linker-payload platform technologies that define competitive advantage.
The modality's economics changed when topoisomerase I inhibitor payloads paired with high drug-to-antibody ratios demonstrated activity even in tumors with low antigen expression, most visibly in breast cancer, where treatment of HER2-low disease dramatically enlarged the eligible population beyond classical HER2-positive patients. That bystander-effect chemistry has drawn conjugates into earlier treatment lines and into lung and gastric cancers, displacing conventional chemotherapy rather than merely following it. Deal-making is a defining structural feature: high-value licensing agreements for TROP2, HER3, and B7-H4 programs, many originating with Chinese biotechnology companies, have made ADC platforms among the most traded assets in oncology. Managing class toxicities such as interstitial lung disease and ocular effects, and sequencing conjugates that share payload classes, are the clinical questions most likely to shape future positioning.
North America generates the largest revenue on rapid uptake in breast and bladder cancer, Europe follows with staged reimbursement, and Asia Pacific rises on both patient volume and its growing role as a discovery and manufacturing base. The field mixes global oncology leaders with platform specialists supplying conjugation chemistry.
The InsightAce study presents revenue forecasts in US$ across payload, linker, indication, and regional segments for 2026-2035, including segment trend analysis, competitive landscape assessment, and company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibody Drug Conjugate Market Snapshot
Chapter 4. Global Antibody Drug Conjugate Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Payload Type Estimates & Trend Analysis
5.1. Payload Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Payload Type:
5.2.1. Auristatins
5.2.2. Topoisomerase I Inhibitor Payloads
5.2.3. Maytansinoids
5.2.4. Calicheamicins
5.2.5. Other Payloads
Chapter 6. Market Segmentation 2: By Linker Type Estimates & Trend Analysis
6.1. Linker Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Linker Type:
6.2.1. Cleavable Linkers
6.2.2. Non Cleavable Linkers
Chapter 7. Market Segmentation 3: By Indication Estimates & Trend Analysis
7.1. Indication & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
7.2.1. Breast Cancer
7.2.2. Urothelial Cancer
7.2.3. Lymphomas
7.2.4. Lung Cancer
7.2.5. Gynecologic Cancers
7.2.6. Other Indications
Chapter 8. Antibody Drug Conjugate Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. Pfizer
10.2. AstraZeneca
10.3. Daiichi Sankyo
10.4. F. Hoffmann-La Roche
10.5. Gilead Sciences
10.6. Astellas Pharma
10.7. AbbVie
10.8. GSK
10.9. Johnson & Johnson
10.10. ADC Therapeutics
10.11. Mersana Therapeutics
10.12. Sutro Biopharma
10.13. Duality Biologics
10.14. Byondis
10.15. Heidelberg Pharma
圖表清單 List of Tables & Figures
Table 1. Global Antibody Drug Conjugate Market Revenue Forecast by Payload Type, 2026-2035 (US$ Mn)
Figure 1. Global Antibody Drug Conjugate Market Segmentation Overview
Table 2. Global Antibody Drug Conjugate Market Revenue Forecast by Linker Type, 2026-2035 (US$ Mn)
Figure 2. Global Antibody Drug Conjugate Market Share by Payload Type, 2026 & 2035
Table 3. Global Antibody Drug Conjugate Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 3. HER2-Low Breast Cancer Eligible Population Expansion Analysis
Table 4. North America Antibody Drug Conjugate Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Global Antibody Drug Conjugate Market Share by Indication, 2026 & 2035
Table 5. Europe Antibody Drug Conjugate Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. ADC Licensing and Partnership Deal Landscape by Target Class
Table 6. Asia Pacific Antibody Drug Conjugate Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Antibody Drug Conjugate Growth Opportunity Analysis
Table 7. Latin America Antibody Drug Conjugate Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Earlier Line Adoption Trend Across Breast, Urothelial, and Lung Cancer
Table 8. Middle East & Africa Antibody Drug Conjugate Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Antibody Drug Conjugate Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們